Naloxone Use by Emergency Medical Services During the COVID-19 Pandemic: A National Survey.
Analgesics, Opioid
/ toxicity
COVID-19
Coronavirus Infections
/ epidemiology
Drug Overdose
/ drug therapy
Emergency Medical Services
/ statistics & numerical data
Humans
Infection Control
Naloxone
/ administration & dosage
Narcotic Antagonists
/ administration & dosage
Nasal Sprays
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
Surveys and Questionnaires
United States
/ epidemiology
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
9
10
2020
medline:
27
11
2020
entrez:
8
10
2020
Statut:
ppublish
Résumé
The COVID-19 epidemic in the United States has hit in the midst of the opioid overdose crisis. Emergency medical services (EMS) clinicians may limit their use of intranasal naloxone due to concerns of novel coronavirus infection. We sought to determine changes in overdose events and naloxone administration practices by EMS clinicians. Between April 29, 2020 and May 15, 2020, we surveyed directors of EMS fellowship programs across the US about how overdose events and naloxone administration practices had changed in their catchment areas since March 2020. Based on 60 respondents across all regions of the country, one fifth of surveyed communities have experienced an increase in opioid overdoses and events during which naloxone was administered, and 40% have experienced a decrease. The findings varied by region of the country. Eighteen percent of respondents have discouraged or prohibited the use of intranasal naloxone with 10% encouraging the use of intramuscular naloxone. These findings may provide insight into changes in opioid overdose mortality during this time and assist in future disaster planning.
Identifiants
pubmed: 33031212
doi: 10.1097/ADM.0000000000000746
pmc: PMC7647432
pii: 01271255-202012000-00031
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotic Antagonists
0
Nasal Sprays
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e369-e371Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
Leong YC, Verbeek PR. Does intranasal naloxone administration increase the risk of 2019 coronavirus disease transmission? CJEM 2020; 1–2. doi:10.1017/cem.2020.395.
doi: 10.1017/cem.2020.395
Centers for Disease Control and Prevention. Opioid Overdose, Understanding the Epidemic. 2020. Available at: https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed June 1, 2020.
Alter A, Yeager C. The consequences of COVID-19 on the overdose epidemic: Overdoses are increasing. 2020. Available at: http://www.odmap.org/Content/docs/news/2020/ODMAP-Report-May-2020.pdf. Accessed June 1, 2020.
American Medical Association. Issue brief: Reports of increases in opioid- related overdose and other concerns during COVID pandemic. Advocacy Resource Center 2020. Available at: https://www.ama-assn.org/system/files/2020-05/issue-brief-increases-in-opioid-related-overdose.pdf. Accessed June 1, 2020.
Substance Abuse and Mental Health Services Administration. Coronavirus (COVID-19). 2020. Available at: https://www.samhsa.gov/coronavirus. Accessed June 1, 2020.
Feder S. Overdose calls are rising, but some police in Indiana and Texas have been banned from giving a ’life-saving’ drug. Business Insider 2020.
Williams K, Lang ES, Panchal AR, et al. Evidence-based guidelines for EMS administration of naloxone. Prehosp Emerg Care 2019; 23 (6):749–763.
Chou R, Korthuis PT, McCarty D, et al. Management of suspected opioid overdose with naloxone in out-of-hospital settings: a systematic review. Ann Intern Med 2017; 167 (12):867–875.
Faul M, Dailey MW, Sugerman DE, Sasser SM, Levy B, Paulozzi LJ. Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities. Am J Public Health 2015; 105 Suppl 3: (Suppl 3): e26–e32.
Dietze P, Jauncey M, Salmon A, et al. Effect of intranasal vs intramuscular naloxone on opioid overdose: a randomized clinical trial. JAMA Netw Open 2019; 2 (11):e1914977.